Biocytogen 
BIOCYTOGEN
Innovative models to empower health sciences BIOCYTOGEN was founded in 2009 and is headquartered in Beijing, with three affiliates both in the U.S. and China. We are a professional service provider specializing in gene targeted animal model generation to support basic research, preclinical in vivo efficacy studies, and pharmacological services for antibody drug discovery and development.

Biocytogen Insights

Our technology allows research scientists and biomedical professionals to advance their research discoveries. Ultimately, these breakthroughs may lead to disease therapies and improve human health.
Gene Targeting Services

Extreme Genome Editing (EGE) System

Based on CRISPR/Cas9, our innovative EGE system significantly increases homologous recombination (HR) efficiency, saving time on screening founder mice. EGE is compatible with large DNA fragment insertions in mice, rats, and cell lines.

Southern blot analysis, an integral part of the EGE workflow, is used to rule out random genomic insertions.



Animal Models and Cell Lines

The AAALAC accredited Haimen Animal Center is capable to raise 3,000,000 Specific Pathogen Free (SPF) animals, continuously providing animal models including highly immune-deficient B-NDG® mouse models and humanized immune checkpoint mouse models. 


Innovative models to empower health sciences
Preclinical Services

Taking advantage of a wealth of experience in animal model development, Biocytogen has independently generated and validated a series of immune checkpoint humanized mice. We have the most comprehensive single and double humanized immune checkpoint mouse models in-stock, including B-hPD-1, B-hPD-L1, B-hOX40, B-h4-1BB, and B-hCTLA4.


Antibody R&D Services

Using our humanized mouse models, we are able to carry out preclinical in vivo studies. These include pharmacodynamics/pharmacokinetics (PK/PD), toxicity, biomarkers and other research experiments, providing reliable data support for clinical trials of tumor antibody drugs. Several products have entered the Chemistry and Manufacturing Controls (CMC) stage and will be starting clinical trials in both China and the U.S.



© 2018 Beijing Biocytogen Co., Ltd. All rights reserved. Technical support: fast help cloud
in the section of your HTML pages